Operator
Good day, and welcome to the Invivyd REVOLUTION Program and Measles Replace Convention Name. [Operator Instructions] Please observe, this name is being recorded. I’d now like to show the decision over to Katie Falzone, Senior Vice President of Finance. Please go forward.
Katie Falzone
Senior Vice President of Finance
Thanks, Michelle. A short time in the past, we issued a press launch saying an replace on our REVOLUTION program progress and development of our novel potential first- and best-in-class measles monoclonal antibody candidate for the therapy and prevention of measles. That press launch and the slides which are getting used on at the moment’s webcast might be discovered within the Buyers part of the Invivyd web site underneath the Press Launch and Occasions and Displays part, respectively.
Right now’s dialogue will probably be led by Marc Elia, Chairman of Invivyd’s Board of Administrators. He’s joined by Dr. Robert Allen, Chief Scientific Officer; and Dr. Michael Mina, Chief Medical Officer.
Throughout at the moment’s dialogue, we will probably be making forward-looking statements regarding, amongst different issues, our analysis and growth actions, our regulatory plans, our future prospects and different statements that aren’t historic information. These forward-looking statements are lined inside the which means of the Non-public Securities Litigation Reform Act and are topic to varied dangers, assumptions and uncertainties which will change over time and trigger our precise outcomes to vary materially from these expressed or implied at the moment. These forward-looking statements converse solely as of the date of
